TORONTO, July 15, 2014 — Proteocyte Diagnostics, a company with a unique test for early
identification of oral cancers, announced today that it has officially joined MaRS» SVX (Social Venture Connexion).
Proteocyte Diagnostics Inc., a company with a unique test for early
identification of oral cancers, today announced an investment by Freycinet Investments, made possible by MaRS» SVX (Social Venture Connexion) impact investing platform.
Proteocyte Diagnostics, a company with a unique test for early
identification of oral cancers, announced today that it has officially joined MaRS» SVX (Social Venture Connexion).
Not exact matches
A general exam before anesthesia, including evaluation
of the bite, preoperative organ testing and
identification of abnormal wear patterns, gum infection, and
oral cancer